Clinical Trials
Myrtle
A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 for Participants with Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (ADOA).
Overview
PYC is conducting the Myrtle study – a Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 for Participants with Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (ADOA)
Who may be eligible?
A patient may be able to participate in the clinical trial if they meet eligibility criteria including (but not limited to):
- Adults at least 18 years of age
- A recent (within 5 years) genetic diagnosis of OPA1 mutation associated ADOA
- A BCVA of between ≤20/40 and ≥20/200
- Principal Investigator
Dr Doron Hickey
PYC is conducting the Myrtle study – a Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 for Participants with Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (ADOA)
Who may be eligible?
A patient may be able to participate in the clinical trial if they meet eligibility criteria including (but not limited to):
- Adults at least 18 years of age
- A recent (within 5 years) genetic diagnosis of OPA1 mutation associated ADOA
- A BCVA of between ≤20/40 and ≥20/200
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.